Enoximone

Enoximone

Clinical data
Trade names	Perfan
AHFS/Drugs.com	International Drug Names
Routes of administration	Intravenous
ATC code	C01CE03 ( WHO )
Legal status
Legal status	UK: POM (Prescription only)
Pharmacokinetic data
Bioavailability	50% (oral)
Protein binding	85%
Metabolism	Liver (oxidation)
Elimination half-life	4 to 10 hours
Excretion	Renal (60 to 70%)
Identifiers
IUPAC name 4-Methyl-5-{[4-(methylsulfanyl)phenyl]carbonyl}-2,3-dihydro-1H-imidazol-2-one
CAS Number	77671-31-9  Y
PubChem CID	53708
DrugBank	DB04880  Y
ChemSpider	48492  Y
UNII	C7Z4ITI7L7
KEGG	D04004  Y
ChEMBL	ChEMBL249856  Y
CompTox Dashboard (EPA)	DTXSID8045147
Chemical and physical data
Formula	C12H12N2O2S
Molar mass	248.30 g·mol−1
3D model (JSmol)	Interactive image
Melting point	255 to 258 °C (491 to 496 °F) (decomposes)
SMILES O=C(/C1=C(/NC(=O)N1)C)c2ccc(SC)cc2
InChI InChI=1S/C12H12N2O2S/c1-7-10(14-12(16)13-7)11(15)8-3-5-9(17-2)6-4-8/h3-6H,1-2H3,(H2,13,14,16) Y Key:ZJKNESGOIKRXQY-UHFFFAOYSA-N Y
(verify)

Enoximone (INN, trade name Perfan) is an imidazole phosphodiesterase inhibitor. It is used in the treatment of congestive heart failure and is selective for phosphodiesterase 3. ^[1]

References

1. Boldt J, Suttner S (September 2007). "Combined use of ultra-short acting beta-blocker esmolol and intravenous phosphodiesterase 3 inhibitor enoximone". Expert Opin Pharmacother. 8 (13): 2135–47. doi:10.1517/14656566.8.13.2135. PMID   17714066. S2CID   46021219.

External links

• Media related to Enoximone at Wikimedia Commons